{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78.6","upperLimit":"98.4","value":"88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"This is a single-institution phase II study. The primary endpoint is to determine 2-year progression-free survival for patients with locally or regionally advanced HNSCC treated with concurrent intensity modulated radiation therapy (IMRT) + cisplatin + bevacizumab.\n\nbevacizumab\n\ncisplatin\n\nconventional surgery\n\nintensity-modulated radiation therapy","id":"OG000","title":"IMRT + Cisplatin + Bevacizumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Survival Rate: Percentage of Participants Who Survived","type":"SECONDARY","unitOfMeasure":"percentage of participants"}